Gotowa bibliografia na temat „Consulting”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Consulting”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Consulting"
1
Dib, Rita Wilson, Xiqi Li, Samuel Shelburne, Anne-Marie Chaftari, Ray Y. Hachem, Ruth Reitzel, Nylev Vargas-Cruz, Thomas L. Holland, Vance G. Fowler i Issam Raad. "1036. Whole Genome Sequencing Analysis of a Large Cohort of Staphylococcus epidermidis Blood Culture Positive Isolates From a Multicenter Clinical Trial". Open Forum Infectious Diseases 5, suppl_1 (listopad 2018): S309—S310. http://dx.doi.org/10.1093/ofid/ofy210.873.
Pełny tekst źródłaStreszczenie:
Abstract Background Staphylococcus epidermidis is a leading cause of healthcare-associated bacteremia, but the clinical course of S. epidermidis isolated from blood cultures ranges from contamination to serious deep seated infections. We tested the hypothesis that the genetic characteristics of S. epidermidis isolated from blood cultures are significantly associated with disease severity using whole genome sequencing (WGS). Methods We performed WGS of 163 S. epidermidis isolates from a large prospective multicenter, randomized control trial that assessed the safety and efficacy of algorithm-based treatment of patients with staphylococcal bacteremia (ClinicalTrials.gov #NCT01191840). Patient’s infection types were divided into simple (including possible contamination), uncomplicated and complicated bacteremia. Failure was defined as persistent signs and symptoms of infection at 72 hours, persistent bacteremia at 7 days, relapse, complications or overall mortality within 28 days of therapy. WGS was performed using Illumina Miseq, followed by in silico multi-locus sequence type identification and phylogenomic analysis using kSNP. Results Of the 163 isolates analyzed, 39 sequence types (STs) were identified with ST2 and ST5 isolates being most frequently identified (21% and 20%, respectively). ST2 and ST5 isolates were significantly more likely associated with uncomplicated and complicated infections rather than simple bacteremia (P = 0.01 by χ2 test). By multivariate regression analysis, having an ST2 or ST5 S. epidermidis bacteremia was an independent predictor of a complicated infection (odds ratio 4.28, 95% CI 1.36–13.42). Using WGS based branching points rather than sequence typing allowed for additional strengthening of the association of S. epidermidis genetic clustering and clinical infection types (figure). Although there was no significant difference in failure rates among patients infected with different STs, ST2/ST5 strains were significantly more likely to cause relapsing infections (85.7%, P = 0.02). Conclusion WGS could offer a prognostic tool in the management of S. epidermidis bacteremia. ST2 and ST5 strains may help predict a complicated bacteremia course which would warrant appropriate antimicrobial therapy. Disclosures T. L. Holland, Basilea: Consultant, Consulting fee. Motif Bio: Consultant and Scientific Advisor, Consulting fee. Theravance: Consultant, Speaker honorarium. Genentech: Consultant, Consulting fee. V. G. Fowler Jr., Debiopharm: Consultant, Consulting fee. Durata: Consultant, Consulting fee. Merck: Consultant and Scientific Advisor, Consulting fee. Cerexa/Actavis/Allergan: Grant Investigator, Grant recipient. Pfizer: Consultant and Grant Investigator, Consulting fee and Grant recipient. Advanced Liquid Logics: Grant Investigator, Grant recipient. NIH: Grant Investigator, Grant recipient. MedImmune: Consultant and Grant Investigator, Consulting fee and Grant recipient. Basilea: Consultant and Grant Investigator, Consulting fee and Grant recipient. Karius: Grant Investigator, Grant recipient. Contrafect: Consultant and Grant Investigator, Consulting fee and Grant recipient. Regeneron: Grant Investigator, Grant recipient. Genentech: Consultant and Grant Investigator, Consulting fee and Grant recipient. Affinergy: Consultant and Grant Investigator, Consulting fee and Grant recipient. Locus: Grant Investigator, Grant recipient. Medical Surface, Inc.: Grant Investigator, Grant recipient. Theravance: Consultant, Consulting fee and Speaker honorarium. Green Cross: Consultant, Speaker honorarium. Grifols: Consultant, Consulting fee. xBiotech: Consultant, Consulting fee. Achaogen: Consultant, Consulting fee. Medicines Co: Consultant, Consulting fee. Novartis: Consultant, Consulting fee. Novadigm: Consultant, Consulting fee. Bayer: Consultant, Consulting fee. Cubist: Consultant, Consulting fee. Debiopharm: Consultant, Consulting fee. Durata: Consultant, Consulting fee. I. Raad, The University of Texas MD Anderson Cancer Center: Shareholder, Licensing agreement or royalty. The Unversity of Texas MD Anderson Cancer Center: Shareholder, Dr. Raad is a co-inventor of the Nitroglycerin-Citrate-Ethanol catheter lock solution technology which is owned by the University of Texas MD Anderson Cancer Center (UTMDACC) and has been licensed to Novel Anti-Infective Technologies LLC, in which UTMDACC and Licensing agreement or royalty.
2
Henderson, Heather, Eric Cober, Sandra S. Richter, Robert Salata, Robert Kalayjian, Richard Watkins, Yohei Doi i in. "1180. Addition of Chronic Kidney Disease Status to Pitt Bacteremia Score Improves Prediction of Mortality in Patients With Carbapenem-Resistant Enterobacteriaceae Infections". Open Forum Infectious Diseases 5, suppl_1 (listopad 2018): S356—S357. http://dx.doi.org/10.1093/ofid/ofy210.1013.
Pełny tekst źródłaStreszczenie:
Abstract Background Carbapenem-resistant Enterobacteriaceae (CRE) infections are associated with high mortality. The Pitt Bacteremia Score (PBS) was developed and validated to predict mortality in bloodstream infections (BSI). The first goal of this analysis is to evaluate whether PBS also predicts mortality in non-BSI infections. Second, we determine whether adding chronic kidney disease (CKD) as a parameter to PBS improves prediction of mortality. Methods The Consortium on resistance against carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE-1) is a prospective multicenter consortium of hospitals. Each patient with CRE infection was included once at the time of the last positive culture episode. Infections were distinguished from colonization using established definitions. Relative risk regression was used to evaluate the association of PBS ≥4 and CKD with 14-day all-cause hospital mortality. Results From December 2011 to June 2016, 364 unique patients were included with the following infections: bloodstream (34%), respiratory (20%), urinary (30%), and wound (16%). Median PBS was 3 (IQR: 2–4); 45% of patients had PBS ≥4. CKD was present in 31% of patients with PBS ≥4 and 20% of patients with PBS <4. All-cause mortality within 14 days of the last positive culture episode was 20%. In multivariable analysis, PBS ≥4 was strongly associated with mortality in patients with bacteremia (PBS ≥4 adjusted RR = 6.1, 95% CI 2.5–14.6, CKD aRR = 1.5, 95% CI 0.9–2.3) and in patients with other infections (PBS ≥4 aRR = 14.0, 95% CI 4.3–44.6, CKD aRR = 1.6, 95% CI 1.0–2.7). Adding CKD as a parameter to the PBS improved mortality prediction, specifically in patients with PBS ≥4 (figure). Conclusion As expected, PBS ≥4 was predictive of the 14-day risk of hospital mortality in this cohort of CRE bacteremic patients. In patients with other CRE infections, PBS ≥4 was also predictive of mortality. In this cohort, adding CKD to the PBS improved prediction of mortality patients with PBS ≥4. Disclosures S. S. Richter, bioMerieux: Grant Investigator, Research grant. BD Diagnostics: Grant Investigator, Research grant. Roche: Grant Investigator, Research grant. Hologic: Grant Investigator, Research grant. Diasorin: Grant Investigator, Research grant. Accelerate: Grant Investigator, Research grant. Biofire: Grant Investigator, Research grant. V. G. Fowler Jr., Merck: Consultant and Scientific Advisor, Consulting fee. Cerexa/Actavis/Allergan: Grant Investigator, Grant recipient. Pfizer: Consultant and Grant Investigator, Consulting fee and Grant recipient. Advanced Liquid Logics: Grant Investigator, Grant recipient. NIH: Grant Investigator, Grant recipient. MedImmune: Consultant and Grant Investigator, Consulting fee and Grant recipient. Basilea: Consultant and Grant Investigator, Consulting fee and Grant recipient. Karius: Grant Investigator, Grant recipient. Contrafect: Consultant and Grant Investigator, Consulting fee and Grant recipient. Regeneron: Grant Investigator, Grant recipient. Genentech: Consultant and Grant Investigator, Consulting fee and Grant recipient. Affinergy: Consultant and Grant Investigator, Consulting fee and Grant recipient. Locus: Grant Investigator, Grant recipient. Medical Surface, Inc.: Grant Investigator, Grant recipient. Theravance: Consultant, Consulting fee and Speaker honorarium. Green Cross: Consultant, Speaker honorarium. Grifols: Consultant, Consulting fee. xBiotech: Consultant, Consulting fee. Achaogen: Consultant, Consulting fee. Medicines Co: Consultant, Consulting fee. Novartis: Consultant, Consulting fee. Novadigm: Consultant, Consulting fee. Bayer: Consultant, Consulting fee. Cubist: Consultant, Consulting fee. Debiopharm: Consultant, Consulting fee. Durata: Consultant, Consulting fee. D. Van Duin, Shionogi: Scientific Advisor, Consulting fee. achaogen: Scientific Advisor, Consulting fee. Allergan: Scientific Advisor, Consulting fee. Astellas: Scientific Advisor, Consulting fee. Neumedicine: Consultant, Consulting fee. T2 Biosystems: Scientific Advisor, Consulting fee. Roche: Scientific Advisor, Consulting fee.
3
Kociolek, Larry, Ciaran P. Kelly, Robyn Espinosa, Maria Budz, Aakash Balaji, Egon Ozer, Robert Tanz, Xinhua Chen i Dale N. Gerding. "976. Clostridium difficile Colonization Molecular Epidemiology and Anti-toxin Serological Responses in Healthy Infants: A Prospective Cohort Study". Open Forum Infectious Diseases 5, suppl_1 (listopad 2018): S39—S40. http://dx.doi.org/10.1093/ofid/ofy209.092.
Pełny tekst źródłaStreszczenie:
Abstract Background Infant C. difficile colonization is common, but the molecular epidemiology and immunologic consequences of colonization are poorly understood. Methods In this prospective cohort study of healthy infants, serial stools collected between 1–2 and 9–12 month olds were tested for glutamate dehydrogenase (detects nontoxigenic or toxigenic C. difficile [TCD]), tcdB PCR (detects TCD), and cultured for C. difficile. Isolates underwent whole genome sequencing and multilocus sequence typing (MLST). Clonal strains were identified by single nucleotide variant (SNV) analysis. TCD was confirmed by BLAST identification of tcdA/tcdB. Serum collected at 9–12 month olds underwent ELISA for measurement of IgA, IgG, and IgM against TCD toxins A and B. For comparison, anti-toxin IgG was measured in cord blood of 50 consecutive full-term deliveries (unrelated to study infants). Arbitrary ELISA units were compared by Wilcoxon rank-sum test. Results Among 32 infants, 16 (50%) had at least one TCD+ stool, 12 of whom were colonized at least 1 m prior to serology measurements (Figures 1 and 2). A variety of STs were identified, and evidence of putative in-home (enrolled siblings) and outpatient clinic transmission was identified (Figure 3). Infants with TCD colonization had significantly greater levels of anti-toxin IgA and IgG compared with non-colonized infants and IgG compared with unrelated cord blood (Table 1). Conclusion Infant C. difficile colonization is a dynamic process with variable strain types and duration. Outpatient clinics may be a C. difficile reservoir for some patients. TCD colonization is associated with a humoral immune response against toxins A and B, but whether natural TCD immunization protects against CDI later in life requires further investigation. Disclosures L. Kociolek, Alere/Techlab: Investigator, Research support. C. P. Kelly, Actelion: Consultant, Consulting fee. Artugen: Consultant, Consulting fee. Facile: Consultant, Consulting fee. GSK: Consultant, Consulting fee. MSD: Consultant, Consulting fee. Seres: Consultant, Consulting fee. Summit: Consultant, Consulting fee. Vedanta: Consultant, Consulting fee. D. N. Gerding, Merck: Scientific Advisor, Consulting fee. Actelion: Scientific Advisor, Consulting fee. DaVolterra: Scientific Advisor, Consulting fee. Summit: Scientific Advisor, Consulting fee. Rebiotix: Medical Officer and Scientific Advisor, Consulting fee. Pfizer: Consultant, Consulting fee. MGB Pharma: Consultant, Consulting fee. sanofi pasteur: Consultant, Consulting fee. Seres: Investigator, Research grant. CDC: Investigator, Research grant. US Dept VA: Investigator, Research grant. Treatment/Prevention of C. difficile: Patent Holder, no license or royalties.
4
Bergin, Stephen P., Adrian Coles, Sara B. Calvert, John Farley, Jonas Santiago, Marcus J. Zervos, Ana Cecilia Bardossy i in. "872. PROPHETIC: Predicting Pneumonia in Hospitalized Patients in the ICU—A Model and Scoring System". Open Forum Infectious Diseases 5, suppl_1 (listopad 2018): S25. http://dx.doi.org/10.1093/ofid/ofy209.056.
Pełny tekst źródłaStreszczenie:
Abstract Background Prospectively identifying patients at highest risk for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) by implementing a risk assessment scoring tool may help focus prevention efforts, optimize the screening process to improve clinical trial feasibility, and enhance development of new antibacterial agents. Methods Within the intensive care units (ICU) of 28 US hospitals, between February 6, 2016 and October 7, 2016, patients hospitalized >48 hours and receiving high levels of respiratory support were prospectively followed for meeting the definition of HABP/VABP recommended in US FDA draft guidance. Patient demographics, medical comorbidities, and treatment exposures were recorded. The association between candidate risk factors and odds of developing HABP/VABP was evaluated with a multivariable logistic regression model. Risk factors were selected using backward selection with α = 0.1 for model inclusion. A web-based scoring system was developed to estimate the risk of HABP/VABP from the risk factors identified. Results A total of 5,101 patients were enrolled, of whom 1,005 (20%) developed HABP/VABp. 4,613 patients were included in the model, excluding 488 (10%) with HABP/VABP at or before enrollment. There are 15 variables included in the model. APACHE II admission score >20 (P < 0.001, OR 2.14, 95% CI 2.00–2.29), admission diagnosis of trauma (P < 0.001, OR 3.31, 95% CI 1.90–5.74), frequent oral or lower respiratory tract suctioning (P < 0.001, OR 2.33, 95% CI 1.81–2.99), and receipt of enteral nutrition (P < 0.001, OR 2.31, 95% CI 1.69–3.16) were the key drivers of increased pneumonia risk. The model demonstrated excellent discrimination (bias-corrected C-statistic 0.861, 95% CI 0.843–0.880). The web-based scoring system can be accessed via this link: https://ctti-habpvabp.shinyapps.io/web_based_tool/. Conclusion Using a web-based scoring system, ICU patients at highest risk for developing HABP/VABP can be accurately identified. Prospective implementation of this tool may assist in focusing additional prevention efforts on the highest risk patients and enhance new drug development for HABP/VABP. Disclosures S. P. Bergin, CTTI: Investigator and Scientific Advisor, Research support and Travel to study related meetings. A. Coles, CTTI: Investigator and Scientific Advisor, Salary. S. B. Calvert, CTTI: Employee, Salary. M. J. Zervos, CTTI: Investigator, Research support. A. C. Bardossy, CTTI: Investigator, Research support. M. Kollef, CTTI: Investigator, Research support. M. J. Durkin, CTTI: Investigator, Research support. M. Sims, CTTI: Investigator, Research support. C. Greenshields, CTTI: Investigator, Research support. B. A. Kabchi, CTTI: Investigator, Research support. H. K. Donnelly, CTTI: Collaborator and Scientific Advisor, Research support and Salary. P. Tenaerts, CTTI: Employee, Salary. P. Gu, CTTI: Collaborator, Research support and Salary. V. G. Fowler Jr., CTTI: Investigator and Scientific Advisor, Research support and Salary. Merck: Consultant, Grant Investigator and Scientific Advisor, Consulting fee, Grant recipient and Research support. Cerexa/Actavis/Allegan: Grant Investigator, Grant recipient. Pfizer: Consultant and Grant Investigator, Consulting fee and Grant recipient. Advanced Liquid Logics: Grant Investigator, Grant recipient. NIH: Investigator, Grant recipient, Research support and Salary. MedImmune: Consultant and Grant Investigator, Consulting fee and Grant recipient. Basilea: Consultant and Grant Investigator, Consulting fee and Grant recipient. Karius: Grant Investigator, Grant recipient. Contrafect: Consultant and Grant Investigator, Consulting fee and Grant recipient. Regeneron: Grant Investigator, Grant recipient. Genentech: Consultant and Grant Investigator, Consulting fee and Grant recipient. Achaogen: Consultant, Consulting fee. Astellas: Consultant, Consulting fee. Arsanis: Consultant, Consulting fee. Affinergy: Consultant, Consulting fee. Bayer: Consultant, Consulting fee. Cerexa: Consultant, Consulting fee. Cubist: Consultant, Consulting fee. Debiopharm: Consultant, Consulting fee. Durata: Consultant, Consulting fee. Grifols: Consultant, Consulting fee. Medicines Co.: Consultant, Consulting fee. Novartis: Consultant, Consulting fee. Novadigm: Consultant, Consulting fee. Theravance: Consultant, Consulting fee and Speaker honorarium. xBiotech: Consultant, Consulting fee. Green Cross: Consultant, Speaker honorarium. T. L. Holland, CTTI: Investigator and Scientific Advisor, Research support and Salary.
5
Bronnenmayer, Matias, Bernd W. Wirtz i Vincent Göttel. "Determinants of perceived success in management consulting". Management Research Review 39, nr 6 (20.06.2016): 706–38. http://dx.doi.org/10.1108/mrr-06-2014-0145.
Pełny tekst źródłaStreszczenie:
Purpose This paper aims to conceptualize perceived management consulting success, derive relevant success factors based on principal-agent theory and the resource-based view as well as investigate the particular factors’ influence. Management consulting has become important for improving the competitiveness of a variety of firms. Surprisingly, there is little empirical evidence clarifying what constitutes a successful management consulting project. Design/methodology/approach The authors conduct a survey to empirically investigate the hypotheses. They develop the survey instrument through a literature review, expert interviews, a pre-test and an item-sorting test. To analyze the data from 348 management consultants, the authors apply structural equation modeling. Additionally, they choose a triangulation approach by asking secondary informants about the originally surveyed consultants’ responses. Findings Initially, the authors develop the second-order construct perceived management consulting success, consisting of the factors compliance with budget and schedule, degree of target achievement, profitability as well as expansion and extension. Additionally, they develop an understanding of management consulting’s success factors. In this regard, five of six factors show a significant impact on perceived management consulting success. Originality/value According to the results, the factor intensity of collaboration is of highest importance for perceived management consulting success. Further, the factors common vision, consultant expertise and top management support show comparably strong significant influences. Yet, the authors have to reject the hypothesis about trust. This result conveys the complicacy of the consultant–client relationship and shows that building a trustful relationship between both parties is hard to accomplish.
6
Farrands, Rob. "Sustaining Dynamic Tension When Consulting To Complex Systems". British Gestalt Journal 10, nr 1 (1.07.2001): 4–12. http://dx.doi.org/10.53667/krwu6742.
Pełny tekst źródłaStreszczenie:
"Abstract: The purpose of this article is to provide an account of the work of an organisation consultant hm a Gestalt perspective. The first describes a particular assignment with a strategy team working on behalf of a multinational oil company in an intense examination of technical and strategic scenarios for the first half of this century. This includes an account of how the consultant struggled to make use of his own bewilderment, and sought to sustain 'stmnger-n~s' in his relationship with the client system. The second part is a more theoretical reflection upon the dialectical forces at play as the consultant creates a consulting approach that seeks to integrate the team around a common story, while also numrhg their connection to the complex world of the larger system. The paper also explores the way in which working with different levels of system requires that mutually exclusive goals have to be held in a dynamic tension. In a final part the consultant considers his Gestalt heritage and how this has influenced the choices he has made on this assignment. Key words: organisation consulting, strategy development, levels of system, system boundaries, presenceI pmms consultin& energy, contact, Gestalt."
7
Choo, Yang-Hyun, Soon-Jin Choo i Seung-Hee Lee. "A Study on Consultant’s Social Value, Learning, Leadership Type Influence on Consulting Flow and Performance". Asian Social Science 14, nr 8 (27.07.2018): 27. http://dx.doi.org/10.5539/ass.v14n8p27.
Pełny tekst źródłaStreszczenie:
The purpose of this study is to investigate consultants in ongoing consulting projects for smaller enterprises to implement an empirical study on the degree of influence of consultant value, consultant learning and consultant leadership type on consulting performance, which have not been mentioned in preceding study. The surveyed were consultants who had provided consulting service to smaller enterprises. For the study, a total of 223 sets of questionnaires were collected but 18 poorly-answered sets were excluded to utilize 205 sets for the study research. As a summary of the results, the social responsibility had a significant effect on consulting Flow whereas social support did not. learning motivation, learning intention and transformational/transactional/servant leadership on consulting Flow found that all of the variables had a significant effect on consulting Flow. In addition to that, social responsibility, support and learning motivation, learning intention and transformational/transactional/servant leadership on consulting satisfaction found that all of the variables significantly affected consulting satisfaction.
8
Wohl, David A., Yazdan Yazdanpanah, Axel Baumgarten, Amanda Clarke, Melanie Thompson, Cynthia Brinson, Debbie Hagins i in. "LB4. A Phase 3, Randomized, Controlled Clinical Trial of Bictegravir in a Fixed-Dose Combination, B/F/TAF, vs. ABC/DTG/3TC in Treatment-Naïve Adults at Week 96". Open Forum Infectious Diseases 5, suppl_1 (listopad 2018): S760—S761. http://dx.doi.org/10.1093/ofid/ofy229.2178.
Pełny tekst źródłaStreszczenie:
Abstract Background Bictegravir (B), a potent INSTI with a high barrier to resistance, is coformulated with emtricitabine (F) and tenofovir alafenamide (TAF) as the FDA-approved single-tablet regimen B/F/TAF. We report Week 96 results from an ongoing phase 3 study comparing B/F/TAF to coformulated dolutegravir, abacavir, and lamivudine (DTG/ABC/3TC) in treatment-naïve adults living with HIV-1. Primary outcome at W48 demonstrated noninferior virologic responses, similar bone and renal profiles, and no viral resistance. Methods We randomized 1:1 HLA-B*5701-negative adults, without HBV and with estimated glomerular filtration rate (eGFR) ≥50 mL/minute to receive blinded B/F/TAF (50/200/25 mg) or DTG/ABC/3TC (50/600/300 mg) with matching placebos QD. Primary endpoint was proportion with HIV-1 RNA <50 copies/mL at W48 (FDA snapshot), with secondary analyses at W96. Noninferiority was assessed with 95% confidence intervals (CI) (12% margin). Other secondary endpoints were safety (adverse events [AEs], laboratory abnormalities) and predefined analyses of bone mineral density (BMD) and measures of renal function (eGFR, proteinuria). Results A total of 629 adults were randomized/treated (314 B/F/TAF, 315 DTG/ABC/3TC). At W96, B/F/TAF was noninferior to DTG/ABC/3TC: 87.9% vs. 89.8%, respectively, achieved HIV-1 RNA <50 copies/mL (difference −1.9%; 95%CI −6.9% to 3.1%, P = 0.45). In per-protocol analysis, 99.6% on B/F/TAF vs. 98.9% on DTG/ABC/3TC achieved HIV-1 RNA <50 copies/mL (P = 0.33). Most common AEs overall were nausea (11% B/F/TAF, 24% DTG/ABC/3TC, P < 0.001), diarrhea (15%, 16%), and headache (13%, 16%). Through W96, no participant had emergent resistance to study drugs. No participant discontinued B/F/TAF due to AEs; five (2%) discontinued DTG/ABC/3TC due to AEs (one after W48). Treatment-related AEs occurred in 28% B/F/TAF vs. 40% DTG/ABC/3TC (P = 0.002); most common was nausea (6%, 17%. P < 0.001). At W96, mean percentage changes in spine and hip BMD were small and similar between groups (table); median change in eGFR was significantly less with B/F/TAF, while median % changes in proteinuria were similar. Conclusion At W96, B/F/TAF was virologically noninferior to DTG/ABC/3TC, with no viral resistance or safety-related discontinuations. B/F/TAF was well tolerated with less nausea than DTG/ABC/3TC and similar bone and renal safety. Disclosures D. A. Wohl, Gilead: Grant Investigator and Scientific Advisor, Consulting fee and Research grant. Y. Yazdanpanah, AbbVie: Consultant, Consulting fee. Bristol-Myers Squibb: Consultant, Consulting fee. Gilead: Consultant, Consulting fee. MSD: Consultant, Consulting fee. Pfizer: Consultant, Consulting fee. Johnson & Johnson: Consultant, Consulting fee. ViiV Healthcare: Consultant, Consulting fee. A. Baumgarten, AbbVie: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium. BMS: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium. Gilead: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium. Janssen-Cilag: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium. MSD: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium. ViiV: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium. A. Clarke, GSK: Scientific Advisor, Consulting fee. Gilead: Conference attendence, Scientific Advisor and Speaker’s Bureau, Conference attendance support, Consulting fee and Speaker honorarium. BMS: Conference attendence, Conference attendance support. Janssen: Conference attendence, Conference attendance support. M. Thompson, Bristol Myers Squibb: Research Contractor, Research support. ViiV Healthcare: Research Contractor, Research support. C. Brinson, Gilead: Investigator, Scientific Advisor and Speaker’s Bureau, Research support and Speaker honorarium. Theratech: Investigator, Research support. BMS: Investigator, Research support. SlieaGen: Investigator, Research support. GSK ViiV: Consultant, Investigator and Scientific Advisor, Consulting fee, Research support and Speaker honorarium. Daiichi Sankyo: Sub Investigator, Research support. Novo Nordisk: Investigator, Research support. Sanofi: Investigator, Research support. Watson: Investigator, Research support. Salix: Investigator, Research support. Janssen: Investigator, Research support. Roche: Investigator, Research support. Colucid: Investigator, Research support. Eisai: Investigator, Research support. Shionogi: Investigator, Research support. Elcelyx: Investigator, Research support. Sangamo: Sub Investigator, Research support. D. Hagins, GlaxoSmithKline: Scientific Advisor and Speaker’s Bureau, Honoraria and Speaker honorarium. ViiV Healthcare: Scientific Advisor and Speaker’s Bureau, Honoraria and Speaker honorarium. Gilead: Scientific Advisor, Honoraria and Speaker honorarium. Bristol-Myers Squibb: Scientific Advisor and Speaker’s Bureau, Honoraria and Speaker honorarium. M. Ramgopal, Gilead: Grant Investigator, Research grant. A. Antinori, AbbVie: Consultant, Consulting fee. BMS: Consultant and Grant Investigator, Consulting fee and Research grant. Gilead: Consultant and Grant Investigator, Consulting fee and Research grant. Janssen-Cilag: Consultant and Grant Investigator, Consulting fee and Research grant. Merck: Consultant, Consulting fee. ViiV Healthcare: Consultant and Grant Investigator, Consulting fee and Research grant. X. Wei, Gilead: Shareholder, Salary and Stock. K. White, Gilead: Employee and Shareholder, Salary and Stock. S. Collins, Gilead: Employee and Shareholder, Salary and Stock. A. Cheng, Gilead: Employee and Shareholder, Salary and Stock. E. Quirk, Gilead: Employee and Shareholder, Salary and Stock. H. Martin, Gilead: Employee and Shareholder, Salary and Stock.
9
Abrahamian, Fredrick M., George Sakoulas, Evan Tzanis, Amy Manley, Judith N. Steenbergen, Anita Das, Paul Eckburg i Paul McGovern. "1347. Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials". Open Forum Infectious Diseases 5, suppl_1 (listopad 2018): S412. http://dx.doi.org/10.1093/ofid/ofy210.1178.
Pełny tekst źródłaStreszczenie:
Abstract Background Skin infections are a significant medical burden for affected individuals and the healthcare system. The purpose of this investigation was to integrate the findings of two randomized studies of omadacycline (OMC) in ABSSSI. Methods OMC in Acute Skin and Skin Structure Infections Study (OASIS)-1 initiated patients on intravenous (IV) OMC or linezolid (LZD) with a possible transition to oral formulation after at least 3 days of IV therapy. OASIS-2 investigated oral-only OMC. Treatment duration in both studies was 7–14 days. Early clinical response (ECR) in the mITT population, the primary endpoint in both studies, was defined as a ≥20% reduction in lesion size at 48–72 hours after treatment initiation. The secondary endpoint was investigator assessment of clinical response (IACR) at post-therapy evaluation (PTE) in the mITT and CE populations, 7–14 days after treatment initiation. Results A total of 691 patients receiving OMC and 689 patients receiving LZD were included. The mean age of patients was 45 years, 64% were male, and 83% enrolled at US sites. Infection types: wound infections (46.8%), cellulitis/erysipelas (30.5%), major abscess (22.7%). Median lesion size was 316 cm2 and 304 cm2 in OMC and LZD patients, respectively. S. aureus was detected in 74.6% of patients, of which 43.4% had MRSA. 71% were mono-microbial Gram-positive infections, 15% were poly-microbial Gram-positive infections. OMC showed similar efficacy to LZD for the primary and secondary endpoints, as well as for mono-microbial and poly-microbial infections (figure). Clinical responses were similar across different infection types, lesion sizes, and baseline pathogens. Treatment-emergent adverse events (TEAEs), most mild or moderate, were reported by 51% and 41% of patients receiving OMC or LZD, respectively. Nausea and vomiting were more frequent for OMC patients in the OASIS-2 oral-only study while receiving the loading dose on Day 1 and 2. Serious AEs were reported by 2.3% and 1.9%, respectively. TEAEs leading to study drug discontinuation were reported by 1.7% and 1.5%, respectively. Conclusion The integrated analysis of OASIS trials showed that oral and IV omadacycline was effective in the treatment of ABSSSI and was safe and generally well-tolerated by patients. Disclosures F. M. Abrahamian, Allergan: Speaker’s Bureau, Speaker honorarium. Melinta: Speaker’s Bureau, Speaker honorarium. Merck: Speaker’s Bureau, Speaker honorarium. Nabriva: Scientific Advisor, Consulting fee. Paratek: Scientific Advisor, Consulting fee. G. Sakoulas, Allergan: Consultant and Speaker, Consulting fee and Speaker honorarium. Sunovion Pharmaceuticals: Speaker, Speaker honorarium. The Medicines Company: Speaker, Speaker honorarium. Paratek Pharmaceuticals: Consultant, Consulting fee. Cidara Therapeutics: Scientific Advisor, Consulting fee. Arsanis Pharmaceuticals: Scientific Advisor, Consulting fee. E. Tzanis, Paratek Pharmaceuticals: Employee, Salary. A. Manley, Paratek Pharmaceuticals: Employee and Shareholder, Salary. J. N. Steenbergen, Paratek Pharmaceuticals: Employee and Shareholder, Salary. A. Das, Achaogen: Consultant, Consulting fee. Cempra: Consultant, Consulting fee. Contrafect: Consultant, Consulting fee. Nabriva: Consultant, Consulting fee. Paratek: Consultant, Consulting fee. Tetraphase: Consultant, Consulting fee. Theravance: Consultant, Consulting fee. Wockhardt: Consultant, Consulting fee. P. Eckburg, Paratek: Consultant, Consulting fee. P. McGovern, Paratek Pharmaceuticals: Employee, Salary.
10
Marty, Francisco M., Per Ljungman, Roy F. Chemaly, Hong Wan, Valerie L. Teal, Joan Butterton, Wendy W. Yeh, Randi Y. Leavitt i Cyrus Badshah. "1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients". Open Forum Infectious Diseases 5, suppl_1 (listopad 2018): S56—S57. http://dx.doi.org/10.1093/ofid/ofy209.136.
Pełny tekst źródłaStreszczenie:
Abstract Background LET prophylaxis through HCT Week 14 was highly effective in preventing clinically significant CMV infection (CS-CMVi), had a good safety profile, and was associated with lower all-cause mortality by HCT Week 24 compared with placebo (PBO). Patients with detectable CMV DNA at randomization were excluded from the trial’s efficacy analyses (NCT02137772). Here we report the outcomes of these patients. Methods We compared patients randomized 2:1 and treated with LET or PBO who had detectable CMV DNA at randomization (n = 70) to those with undetectable CMV DNA (n = 495; primary efficacy population, PEP). CS-CMVi was defined as CMV viremia requiring antiviral preemptive therapy (PET) or CMV disease; patients with missing data were imputed as events. PET was prescribed blinded to study drug. We analyzed CS-CMVi incidence, CMV viral load (VL) kinetics, and mortality using post study vital status. Detectable, nonquantifiable CMV VL (<151 c/mL) was imputed as 150 c/mL. Results Of 70 patients with detectable CMV DNA at randomization (48 LET, 22 PBO), CMV VL was 150 c/mL in 63 patients (range, 150–716). All patients had undetectable CMV VL ≤5 days before randomization. Baseline characteristics were similar to the PEP, except for more patients with myeloablative conditioning (62.9% vs. 48.3%) and longer median days post-HCT to start of study drug (15 days vs. 8 days). Median study drug exposure was 70 days (range, 1–113) in LET group and 14 days (range, 7–99) in PBO group. By HCT Week 14, CS-CMVi occurred in 15 (31.3%) LET-treated patients and 17 (77.3%) PBO patients; CS-CMVi with imputed events were 22 (45.8%) in LET group and 20 (90.9%) in PBO group (difference –44.8%; 95% CI, –64.7% to –24.8%; P < 0.0001). Median CMV VL at time of PET was 413 c/mL (range, 150–31,847) and was similar between groups. Eight patients had quantifiable CMV VL (range, 171–1,728 c/mL) 1 week after starting study drug: 6 did not receive PET (5 LET [10.4%], 1 PBO [4.5%]). CMV VL was undetectable subsequently; other 2 withdrew from study. One (2.1%) LET-treated patient developed breakthrough CMV viremia with a UL56 C325W mutation. HCT Week 48 all-cause mortality was 26.5% in LET and 40.9% in PBO (figure). Conclusion LET prevented CS-CMVi compared with PBO among patients with detectable CMV DNA at randomization. Disclosures F. M. Marty, Merck: Consultant and Investigator, Consulting fee, Research support and Speaker honorarium. Astellas: Consultant and Investigator, Consulting fee and Research support. Chimerix: Consultant and Investigator, Consulting fee and Research support. Fate Therapeutics: Consultant, Consulting fee. GlaxoSmithKline: Consultant, Consulting fee. LFB: Consultant, Consulting fee. Roche Molecular Diagnostics: Consultant, Consulting fee. Shire: Consultant and Investigator, Consulting fee and Research support. Cidara: Investigator, Research support. Ansun: Investigator, Research support. Gilead: Investigator, Research support. WHISCON: Investigator, Research support. P. Ljungman, Merck: Investigator, Research support. AiCuris: Consultant, Consulting fee. Astellas: Investigator, Research support. Oxford Immunotec: Consultant and Investigator, Consulting fee and Research support. R. F. Chemaly, Merck: Consultant and Investigator, Consulting fee and Research support. Chimerix: Consultant and Investigator, Consulting fee and Research support. Astellas: Consultant, Consulting fee. Novartis: Investigator, Research support. Oxford Immunotec: Consultant, Consulting fee. H. Wan, Merck: Employee and Shareholder, Salary. V. L. Teal, Merck: Employee and Shareholder, Salary. J. Butterton, Merck: Employee and Shareholder, Salary. W. W. Yeh, Merck: Employee and Shareholder, Salary. R. Y. Leavitt, Merck: Employee and Shareholder, Salary. C. Badshah, Merck: Employee and Shareholder, Salary.
Rozprawy doktorskie na temat "Consulting"
1
Sharp, Lee-Ann, i n/a. "The role of sport psychology consultant effectiveness within the consulting relationship". University of Otago. School of Physical Education, 2009. http://adt.otago.ac.nz./public/adt-NZDU20090827.122540.
Pełny tekst źródłaStreszczenie:
Within the field of sport psychology the need for effective evaluation is now one of the most pressing requirements, yet it is a need that is often overlooked (Strean, 1998). The evaluation of the individual sport psychology consultant has been neglected in favour of the assessment and evaluation of the methods employed by these individuals. Despite this neglect, the relationship that exists between the sport psychology consultant (SPC) and the athletes they are consulting with is regarded as a significant component in successful sport psychology interventions (Petitpas, Giges & Danish, 1999). Clinical and counselling psychology literatures have demonstrated substantial evidence supporting the positive effect that an open, trusting and collaborative relationship between therapist and client has on therapeutic outcomes (e.g., Horvath, 2006). Yet little is known about the facilitative conditions needed to establish an effective collaborative relationship between the sport psychology consultant and athlete. The first purpose of this research project was to investigate SPCs, elite athletes and coaches' perceptions of the influence of SPC characteristics on the development of athletes' mental skills. The second purpose was to explore the facilitative conditions these individuals believed were necessary for establishing an effective consulting relationship. In order to accomplish these goals, four studies were conducted to assess what SPCs, athletes and coaches believed to be essential for effective consulting. The first study involved the completion of an online Consultant Effectiveness Form by 48 elite athletes; study two involved individual face-to-face interviews with nine elite athletes (6 male and 3 female, mean age = 32.67 years, SD = 11.05, mean competitive experience = 16.67 years, SD = 8.70) from a variety of sports (cricket, rugby, swimming, triathlon, dressage and wheelchair rugby) regarding their opinions of consulting effectiveness. In study three 13 accredited SPCs (9 males and 4 females, mean age = 44.8, SD = 10.6; mean years consulting experience = 11.1, SD = 4.7) were interviewed to examine their perceptions of consulting effectiveness. Finally, study four involved the interviewing of both members of four sport psychology consulting case studies regarding the effectiveness of their individual relationship. An inductive grounded theory approach was employed to analyse the interview data. Following extensive inductive content analysis the concepts and sub-categories that emerged were then organised into broader categories. Results indicated five categories important for an effective consulting relationship; (a) adopt a client-centred consulting approach, in which the SPC demonstrated trust, openness and a clear understanding of their roles and responsibilities; (b) transference and countertransference were a reality of the consulting relationship which the SPC should be aware of; (c) an informal, flexible, collaborative relationship with clear boundaries and the SPC being friendly, but not friends with the client; (d) the client contributions to the consulting relationship included commitment, openness and honesty; and (e) the SPC contributed counselling skills, enthusiasm, fitted in with team culture and worked towards creating client independence. The findings provide clear guidelines for consulting practice to promote the development of effective consulting relationships between sport psychology consultants and their clients.
2
Cantor, Malcolm, i mcantor@austconsgroup com au. "Cross cultural consulting". Swinburne University of Technology. Graduate School of Business, 2000. http://adt.lib.swin.edu.au./public/adt-VSWT20050218.091024.
Pełny tekst źródłaStreszczenie:
This thesis is concerned with cross-cultural consulting. The research examines how a
multinational consulting team worked with a multinational client. The consultants were from Taiwan, Japan, Singapore, Indonesia, USA and Australia and the client was a multinational oil company located on the island of Sumatra in Indonesia. The study employs the narrative theory of Ricoeur together with the research findings
on culture of Hofstede, Trompenaars, Hall, Kluckhorn and Strodtbeck. The study relies on a comparison of national cultural characteristics as they were enacted duringthe conduct of a consulting project. The research emphasises the roles of the consultants, the consulting process and the consulting outcomes.
3
Sandburg, Sabrina Louise. "Consulting business startup". Manhattan, Kan. : Kansas State University, 2008. http://hdl.handle.net/2097/881.
Pełny tekst źródła
4
Missaoui, Jonas, i Christopher Löfstrand. "Managing Management Consulting". Thesis, Uppsala universitet, Företagsekonomiska institutionen, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-194119.
Pełny tekst źródłaStreszczenie:
The management consulting industry is growing. The industryis also described as being exposed to increased pressure fromthe environment. An interesting question is then how resourcesare managed in management consulting firms in order tosustain competitive advantage. The purpose with this thesis isto investigate how firms in the management consulting industrymanage their resources through the lens of the resourcemanagement framework and if there are any signs of change.Through a multiple case study of the processes in two largemanagement consulting firms, the activity (i.e. the use ofresources) perceived as important for the leveraging ofcompetitive advantage is studied. The findings suggest thatcustomers have a much more central part in the resourcemanagement process than depicted in the resourcemanagement framework. The clearest signs of change refer tothe development of new career paths and an increased globalintegration of competencies.
5
Fernandes, Hugo Emanuel Mesquita. "Management consulting lab". Master's thesis, NSBE - UNL, 2011. http://hdl.handle.net/10362/10073.
Pełny tekst źródłaStreszczenie:
A Work Project, presented as part of the requirements for the Award of a Masters Degree in Management from the NOVA – School of Business and EconomicsThe purpose of this study was to investigate the exports generated in the geographical area under the management of ANA. Since the company have been increasing, and is not aware how they have been evolving. The analysis was done through an analytical overview over the company and all the activities that occur in the geographical area. Then, interviews were conducted to identify passengers’ major differences among the Portuguese airports. Based on all of the information were designed out-of-the box ideas to increase the level of exports.
6
Benites, Correa Antero Ricardo, Becerra Carlos Augusto Calderón, Trigo Juan Diego Herrera, Pastuso Roxana Sophia Limo i Galvez Adriana Lorena Vallejos. "Proyecto E-Consulting". Bachelor's thesis, Universidad Peruana de Ciencias Aplicadas (UPC), 2021. http://hdl.handle.net/10757/655420.
Pełny tekst źródłaStreszczenie:
El presente trabajo de investigación tiene como principal objetivo poder presentar un modelo de negocio enfocado en potenciar el conocimiento y habilidades de manejo de plataformas digitales para emprendedores bajo un concepto de agencia de marketing digital. E-Consulting, es una plataforma web orientada a ofrecer una modalidad e-Learning y servicios de herramientas esenciales para el manejo de plataformas digitales. Brindando calidad, facilidad y personalización en los servicios adquiridos por los usuarios. El propósito de este modelo de negocio permitirá que aquellos emprendedores que hagan uso ineficiente de sus redes sociales puedan perfeccionar sus estrategias de marketing y generar ventas en sus negocios propios.
Este trabajo de investigación consta de tres capítulos básicos, los cuales serán detallados a continuación:
Capítulo I: Fundamentos Iniciales, contará con la presentación del equipo de trabajo para el siguiente proyecto de investigación, al igual que la presentación del concepto y explicación de la idea de negocio.
Capítulo II: Validación del Modelo de Negocio, en dicho apartado se procede a realizar un análisis, experimentación y evaluación del comportamiento de los clientes potenciales para nuestra propuesta de negocio. Además, se efectuarán las intenciones de compra que se desarrollaron a través de 3 experimentos en 1 semana y sus respectivas proyecciones de ventas para 3 años.
Capítulo III: En este último capítulo se desarrollará el plan del negocio, un plan estratégico, plan operacional, de recursos humanos, plan de marketing, responsabilidad social empresarial, plan financiero, de financiamiento y valorización que se llevará a cabo en este proyecto.The main objective of this research work is to present a business model focused on enhancing the knowledge and skills of managing digital platforms for entrepreneurs under a concept of digital marketing agency. E-Consulting, is a web platform oriented to offer an e-Learning modality and essential tool services for the management of digital platforms. Providing quality, ease and customization in the services purchased by users. The purpose of this business model will allow those entrepreneurs who make inefficient use of their social networks to perfect their marketing strategies and generate sales in their own businesses. This research work consists of three basic chapters, which will be detailed below: Chapter I: Initial Fundamentals, will include the presentation of the work team for the next research project, as well as the presentation of the concept and explanation of the business idea. Chapter II: Validation of the Business Model, in this section an analysis, experimentation and evaluation of the behavior of potential customers for our business proposal is carried out. In addition, the purchase intentions that were developed through 3 experiments in 1 week and their respective sales projections for 3 years will be made. Chapter III: This last chapter will develop the business plan, a strategic plan, operational plan, human resources, marketing plan, corporate social responsibility, financial plan, financing and valuation that will be carried out in this project.
Trabajo de investigación
7
Giribaldi, del Risco Romina Maria. "Consulting report – Canvia". Master's thesis, Pontificia Universidad Católica del Perú, 2019. http://hdl.handle.net/20.500.12404/15113.
Pełny tekst źródłaStreszczenie:
Canvia is a Peruvian company owned by Advent International, which is one of the
five largest private equity investment funds in the world. Canvia provides digital
transformation services to clients to achieve the concrete business results, operating the
following four business units: (a) service desk, (b) digital service, (c) business operation, and
(d) cloud. The service desk unit is currently earning a low rate of margin. The main problem
identified is a contract of service negotiated with Tiendas por Departamento Ripley, a
Chilean retail company; and Banco Ripley Peru, a Chilean bank. According to the terms of
this contract, Canvia provides their service desk services to both companies in Peru, by which
the company receives a flat fee, independently of the number of tickets Canvia team resolves.
This results in a constant revenue stream for Canvia and the increasing costs they have faced,
resulted in financial losses to the company. However, at the moment, they are generating
profits because of some changes introduced by the new Senior Manager. In this sense, the
service desk unit, in particular Ripley’s account, is interested in look for any solution that
generate a steady 20% profit margin.
After reviewing the relevant literature, we have developed three alternatives of
solutions, which are composed by several activities, which have been evaluated according to
factors such as costs, innovation, risk, value added, feasibility and Canvia’s feedback. Our
proposed solutions are a mix of these activities, which try to reduce costs but also increase
Service Desk Unit’s flat revenues. The solutions are the implementation of a training website
and the provision of training services to Ripley’s employees who manipulate embosadoras.
However, since the success of these alternatives does not depend only on Canvia, it is
concluded that the generation of a steady 20% profit margin for the Ripley account will not
be possible if Canvia does not remain contracted by Ripley to provide additional services.Canvia es una compañía peruana parte de Advent International, uno de los cinco fondos de inversión de capital privado más grandes del mundo. Canvia proporciona servicios de transformación digital a sus clientes para lograr resultados comerciales concretos, operando las siguientes cuatro unidades comerciales: (a) service desk, (b) servicio digital, (c) operación comercial y (d) cloud. La unidad de service desk está afrontando un bajo desempeño financiero. El principal problema identificado es el contrato de servicio negociado con Tiendas por Departamento Ripley, una empresa minorista chilena; y Banco Ripley Peru, un banco chileno. De acuerdo con los términos de este contrato, Canvia brinda sus servicios de service desk a ambas compañías, a cambio de una tarifa fija que no incrementa a pesar de que el número de tickets por resolver siga aumentando. Esto resulta en un flujo constante de ingresos para Canvia y un aumento significativo de costos, lo cual causó que la compañía llegue a tener pérdidas financieras. Sin embargo, actualmente están generando ganancias por algunos cambios realizados por el nuevo Gerente de Proyecto. En este sentido, la cuenta de Ripley en la unidad de service desk, está interesada en buscar cualquier solución que genere un margen estable del 20%. Después de revisar la literatura relevante, se han desarrollado tres alternativas de soluciones, compuestas por varias actividades, que han sido evaluadas de acuerdo a ciertos factores. La solución propuesta es una combinación de estas actividades - la implementación de un sitio web de capacitación y la provisión de servicios de capacitación sobre embosadoras - con el objetivo de reducir costos y también aumentar los ingresos fijos de la unidad. Sin embargo, dado que el éxito de estas alternativas no depende solo de Canvia, se concluye que la generación de un margen de beneficio estable del 20% para la cuenta de Ripley no será posible si Canvia no permanece contratado por Ripley para la provisión de servicios adicionales.
Tesis
8
Perez, Paredes Elio David. "Consulting report – Mipaku". Master's thesis, Pontificia Universidad Católica del Perú, 2019. http://hdl.handle.net/20.500.12404/15151.
Pełny tekst źródłaStreszczenie:
MiPaku is a small, socially conscious fashion brand specializing in the design,
manufacture, and sales of high-quality alpaca wool and cotton blended garments. The
company is essentially an outgrowth of D’Peru textiles, which is an already established selfsustainable
business that has been running since 2010. While Mipaku offers its products
under its own brand name, D’Peru Textiles is a white-label label manufacturer of high-end
alpaca wool and cotton blended garments. The company is based in Lima, Peru, and, at
present, employs a total of 12 persons. Notably, Mipaku shares its production facilities, staff,
warehousing, and ownership with D’Peru Textiles. Mipaku generates annual sales of less
than US$10,000.
Mipaku wants to grow yet is unsure of how to do so. Accordingly, the main
problem(s) addressed in the consulting report concern market selection and modes of entry.
In order to address the problem of market selection, an integrated market selection model is
designed (based upon relevant literature) and employed to determine which markets Mipaku
should pursue. Results from the model are complemented by qualitative research and
identified that the United States, Germany, and the United Kingdom are the top markets for
further pursuit.
Following market selection, entrance strategies for each market are designed and
organized into a Gantt chart. Moreover, the proposed implementation offers legal
requirements, distribution channels, cost strategies, and a list of trade shows, boutiques, and
other potential customers. Finally, it is analyzed the qualitative and quantitative outcomes
that give the expected net present value and internal rate of return. To conclude, it is
projected that if Mipaku implements the recommendations outlined in the consulting report,
they will indeed accomplish their goal of increasing sales and growing their brand.MiPaku es una pequeña empresa de moda especializada en el diseño, fabricación y venta de prendas de alta calidad de lana de alpaca y algodón. Mipaku es esencialmente una extensión de D'Peru Textiles, el cual es un negocio autosustentable ya establecido que ha estado funcionando desde 2010. La principal diferencia es que Mipaku ofrece sus productos bajo su propia marca, mientras que D'Peru Textiles es un fabricante de prendas combinadas de algodón y lana de alpaca de alta gama de etiquetas de marca blanca. La empresa tiene su sede en Lima, Perú, y, en la actualidad, emplea a un total de 12 personas. En particular, Mipaku comparte sus instalaciones de producción, personal, almacenamiento y propiedad con D’Peru Textiles. Mipaku genera ventas anuales de menos de US$ 10,000. Mipaku quiere crecer, pero aún no está segura de cómo hacerlo. En consecuencia, los principales problemas abordados en esta tesis de consultoría se refieren a la selección del mercado y los modos de entrada. Para abordar el problema mencionado, se ha diseñado un modelo integrado de selección de mercados (basado en la literatura relevante) el cual es empleado para determinar qué mercados ofrecen potencial de crecimiento para Mipaku. Los resultados del análisis cuantitativo se complementan con análisis cualitativos, identificando como resultado que, Estados Unidos, Alemania y el Reino Unido son los principales mercados en los cuales Mipaku debe centrarse. Después de la selección del mercado, se diseña las estrategias de entrada para cada mercado las cuales se organizan en un diagrama de Gantt. Además, propone una implementación la cual contempla requisitos legales, canales de distribución, estrategias de costos y una lista de ferias, boutiques y otros clientes potenciales. Finalmente, se analizan los resultados cualitativos y cuantitativos para determinar el esperado valor presente neto y la tasa interna de retorno. Para concluir, se propone concretas recomendaciones con el objetivo de que Mipaku logre aumentar sus ventas y hacer crecer su marca.
Tesis
9
Norström, Markus. "Creativity in consulting". Thesis, Uppsala universitet, Institutionen för informationsteknologi, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-393321.
Pełny tekst źródłaStreszczenie:
This thesis focuses on defining what creativity is, how it can be encouraged and how this is done in consulting firms today. This is done through a literary study to gather information on what creativity is and how to encourage creativity effectively in software consulting. During the cours of the work, a case study which aims to gather where the company is acting correct according to the literature and what could be improved was done in the consultant firm Dewires' offices. This is further explored with the help of both focus group interviews and individual interviews where the recognised factors of creativity in companies found in the literature is discussed with the employees. The results are then presented and discussed to find what can be improved upon in the future to further encourage the employees to be more creative.
10
Skovgaard, Smith Irene. "Management consulting in action : value creation and ambiguity in client-consultant relations /". Copenhagen : Business School, 2008. http://www.gbv.de/dms/zbw/569451086.pdf.
Pełny tekst źródłaKsiążki na temat "Consulting"
1
Scheer, August-Wilhelm, i Alexander Köppen, red. Consulting. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-98079-4.
Pełny tekst źródła
2
Scheer, August-Wilhelm, i Alexander Köppen, red. Consulting. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-56459-8.
Pełny tekst źródła
3
Stecki, Leopold. Consulting. Toruń: Towarzystwo Naukowe Organizcji i Kierownictwa "Dom Organizatora", 1997.
Znajdź pełny tekst źródła
4
Consultants, Institute of Management. Consulting. London: Capital, 1994.
Znajdź pełny tekst źródła
5
Pinault, Lewis. Consulting Demons. New York: HarperCollins, 2008.
Znajdź pełny tekst źródła
6
Bodenstein, Robert, i Josef Herget. Consulting Governance. Berlin, Heidelberg: Springer Berlin Heidelberg, 2022. http://dx.doi.org/10.1007/978-3-662-65299-2.
Pełny tekst źródła
7
Nissen, Volker, red. Consulting Research. Wiesbaden: DUV, 2007. http://dx.doi.org/10.1007/978-3-8350-9236-5.
Pełny tekst źródła
8
Chereau, Philippe, i Pierre-Xavier Meschi. Strategic Consulting. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-64422-6.
Pełny tekst źródła
9
Nissen, Volker, i Bruno Klauk, red. Studienführer Consulting. Wiesbaden: Springer Fachmedien Wiesbaden, 2012. http://dx.doi.org/10.1007/978-3-8349-4466-5.
Pełny tekst źródła
10
Lapygin, YUriy. Management consulting. ru: INFRA-M Academic Publishing LLC., 2017. http://dx.doi.org/10.12737/24402.
Pełny tekst źródłaStreszczenie:
The textbook contains systematized material on key topics of the discipline "Management consulting", including information about the goals and objectives of consulting work, the organization of the consulting system, methods and methods of diagnostics and testing of the objects under study, among which may be enterprises and organizations, management systems, labor and training teams.
The textbook includes exercises, business games, tests, analysis of specific situations that arise in the business environment, on the materials of which practical training sessions can be built.
The thematic scope and depth of the textbook material fully meet the requirements of the Federal state educational standard of higher education of the last generation.
The publication is intended for students and teachers of higher education institutions, postgraduates, as well as managers of personnel management services and consultants on management and organizational development.
Części książek na temat "Consulting"
1
Kandola, Binna. "Consulting". W The Experience of Managing, 49–65. London: Palgrave Macmillan UK, 1999. http://dx.doi.org/10.1007/978-1-349-27328-7_6.
Pełny tekst źródła
2
Hennes, Cathryn A. "Consulting". W Career Pathways in Adult Education, 100–108. New York: Routledge, 2023. http://dx.doi.org/10.4324/9781003259602-13.
Pełny tekst źródła
3
Eden, Lorraine, Kathy Lund Dean i Paul M. Vaaler. "Consulting". W The Ethical Professor, 193–99. 1 Edition. | New York : Routledge, 2018.: Routledge, 2018. http://dx.doi.org/10.4324/9781351049429-28.
Pełny tekst źródła
4
Curtis, Graham. "Consulting". W The Complexity of Consultancy, 38–59. London: Routledge, 2022. http://dx.doi.org/10.4324/9781003095941-3.
Pełny tekst źródła
5
Scheer, A. W., A. Köppen i S. Hans. "Consulting: Ein Überblick". W Consulting, 1–10. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-56459-8_1.
Pełny tekst źródła
6
Erbach, F., i A. Köppen. "Electronic Business-Potenziale analysieren und nutzen". W Consulting, 223–34. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-56459-8_10.
Pełny tekst źródła
7
Pfüller, Gottfried. "Consulting-Schwerpunkte bei der Entwicklung eines Application Service Providers (ASP)". W Consulting, 235–49. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-56459-8_11.
Pełny tekst źródła
8
Köppen, A., i M. Nüttgens. "Open Source: Strategien für die Beratung". W Consulting, 251–61. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-56459-8_12.
Pełny tekst źródła
9
Scholz, C., i V. Stein. "F Unternehmensberater — Ein Berufsbild unter darwiportunistischer Lupe". W Consulting, 263–71. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-56459-8_13.
Pełny tekst źródła
10
Forster, R. "Kommunikation in Beratungsprozessen". W Consulting, 11–40. Berlin, Heidelberg: Springer Berlin Heidelberg, 2001. http://dx.doi.org/10.1007/978-3-642-56459-8_2.
Pełny tekst źródłaStreszczenia konferencji na temat "Consulting"
1
Hutchinson, Linda. "Consulting". W the 19th annual ACM SIGUCCS conference. New York, New York, USA: ACM Press, 1991. http://dx.doi.org/10.1145/122898.122922.
Pełny tekst źródła
2
Fermann, Carla J. "On-line consulting for the on-line consultant". W the 19th annual ACM SIGUCCS conference. New York, New York, USA: ACM Press, 1991. http://dx.doi.org/10.1145/122898.122911.
Pełny tekst źródła
3
Andre, Patrick G. "Professional Consulting". W 2018 IEEE Symposium on Electromagnetic Compatibility & Signal/Power Integrity (EMCSI). IEEE, 2018. http://dx.doi.org/10.1109/emcsi.2018.8495176.
Pełny tekst źródła
4
Sheddon, Mark, i Wayne Schroeder. "Electronic consulting". W the 19th annual ACM SIGUCCS conference. New York, New York, USA: ACM Press, 1991. http://dx.doi.org/10.1145/122898.122962.
Pełny tekst źródła
5
Eggers, Mark D. "Electronic consulting". W the 14th annual ACM SIGUCCS conference. New York, New York, USA: ACM Press, 1986. http://dx.doi.org/10.1145/324239.324258.
Pełny tekst źródła
6
MacVicar, Duncan. "The business and financial aspects of a consulting business". W OSA Annual Meeting. Washington, D.C.: Optica Publishing Group, 1993. http://dx.doi.org/10.1364/oam.1993.whh.3.
Pełny tekst źródła
7
Chitakornkijsil, Pranee. "Ethics in consulting and professionalism, consulting for performance improvement, and consulting in various aspect of management". W 2011 International Summer Conference of Asia Pacific Business Innovation and Technology Management (APBITM). IEEE, 2011. http://dx.doi.org/10.1109/apbitm.2011.5996312.
Pełny tekst źródła
8
Evron, C. D. "Consulting Software Services". W Electro International, 1991. IEEE, 1991. http://dx.doi.org/10.1109/electr.1991.718250.
Pełny tekst źródła
9
Groth, W. B. "Consulting in telecommunications". W Proceedings of SOUTHCON '94. IEEE, 1994. http://dx.doi.org/10.1109/southc.1994.498158.
Pełny tekst źródła
10
Harrington, Roy E. "Consulting Engineering Overseas". W 3rd Agricultural Machinery Conference (1987). 400 Commonwealth Drive, Warrendale, PA, United States: SAE International, 1987. http://dx.doi.org/10.4271/872021.
Pełny tekst źródłaRaporty organizacyjne na temat "Consulting"
1
Bosiljevac, Thomas. ? Rachel Wood Consulting ? Viga Span Tables. Office of Scientific and Technical Information (OSTI), październik 2022. http://dx.doi.org/10.2172/1898254.
Pełny tekst źródła
2
Hausner, Beatrix, Samira Karner, Hannah Tomasi i Azadeh Badieijaryani. Energy consulting: A tool for inclusion? Users TCP, 2023. http://dx.doi.org/10.47568/7xr134.
Pełny tekst źródłaStreszczenie:
This case study was conducted within the framework of the Austrian task participation IEA User-Centred Energy Systems Empowering all: Gender equality for the energy transition and analyzes to what extent the instrument of company-independent energy consulting in Austria addresses different target groups and takes gender and diversity aspects into account. Energy efficiency, climate neutrality in heating and electricity consumption are relevant aspects for the implementation of the energy transition. In addition, longer-term cost reduction for energy use is increasingly relevant for consumers and households. In Austria, therefore, company-independent energy consulting is offered and required renovations are partially subsidized (Stadt Wien, 2022). From a gender and diversity perspective, the following questions arise in this context: Who can take advantage of energy consulting? Who benefits from energy consulting? Are gender aspects, migration, age and socio-economic factors, as well as the overlaps of mentioned aspects (intersectionality) taken into account? What should be considered in gender and diversity friendly energy consulting? What could be a suitable approach for gender- and diversity-friendly energy consulting? In order to answer these questions, results of the international literature on the aspect of inclusion in energy consulting were first compiled, which were used for the development of the guideline for the data collection tools and for the data analysis. Based on this, internet research on the implementation of company-independent energy consulting and its funding opportunities in Austria was conducted. The unanswered questions about the systematics and processes of energy consulting were answered in a semi-structured expert interview with a person who conducts energy consulting. The case study is structured as follows: First, essential terms are explained. Then, the relevance of the case study for Austria as well as the international state of research are presented. This is followed by the results of the research and the interview along the guiding themes and the discussion of the results. Finally, the results are summarized, and recommendations are elaborated.
3
Prowler, D. Procuring Low-Energy Design and Consulting Services. Office of Scientific and Technical Information (OSTI), marzec 1999. http://dx.doi.org/10.2172/12218.
Pełny tekst źródła
4
Jensen, Richard, Jerry Thursby i Marie Thursby. University-Industry Spillovers, Government Funding, and Industrial Consulting. Cambridge, MA: National Bureau of Economic Research, luty 2010. http://dx.doi.org/10.3386/w15732.
Pełny tekst źródła
5
Sturdy, Andrew. Consulting for Covid: outsourced experts or overpaid temps? Redaktor Lachlan Guselli. Monash University, sierpień 2023. http://dx.doi.org/10.54377/d1fd-1e41.
Pełny tekst źródła
6
Guthrie, James, Jane Andrew i Erin Twyford. Powerful firms that put the ‘con’ into consulting. Redaktor Lachlan Guselli. Monash University, sierpień 2023. http://dx.doi.org/10.54377/11e4-eaa4.
Pełny tekst źródła
7
Rosenbaum, Sara. When Medicaid Unwinding Meets AI: In the Matter of DeLoitte Consulting. Milbank Memorial Fund, luty 2024. http://dx.doi.org/10.1599/2024220.
Pełny tekst źródła
8
Miquel Segarra, S., L. López Font i S. Gil Soldevila. Analysis of communications consulting agencies in Spain: Professional profiles, structure and activity. Revista Latina de Comunicación Social, marzec 2018. http://dx.doi.org/10.4185/rlcs-2018-1266en.
Pełny tekst źródła
9
Ast, Julia R., Philipp Brunner, Nikias Dick, Eva-Maria Mooslechner, Gerlinde Pöchhacker-Tröscher i Herwig W. Schneider. Evaluation of KMU.DIGITAL Module Consulting (WKÖ) and Module Implementation (AWS). Synthesis Report. BMAW - Bundesministerium für Arbeit und Wirtschaft, 2023. http://dx.doi.org/10.22163/fteval.2023.627.
Pełny tekst źródłaStreszczenie:
The present analysis encompasses the evaluation of the funding programme KMU.DIGITAL and its two modules Consulting and Implementation since the programme’s relaunch (September 2019 to December 2022). The objective is to assess the programme in terms of its effectiveness and range as well as to formulate evidence-based recommendations for the continuation and future design of the programme. The evaluation ran from January to July 2023.
10
Navia Díaz, María del Rosario. Linden Water Supply Rehabilitation Program (GY-L1036): Technical Analysis. Inter-American Development Bank, czerwiec 2011. http://dx.doi.org/10.18235/0006943.
Pełny tekst źródłaStreszczenie:
The Government of Guyana requested a loan in order to improve the provision of potable water in Linden through improvements in the water production facilities and reductions of NRW levels. Using resources of a technical cooperation (ATN/OC-11805-GY; GY-T1072) an international consulting company (Hydea Consulting) was hired to prepare a master plan and final designs for the rehabilitation of the water supply system in Linden. The information presented in this document is based on the reports developed by Hydea (2011), and the Water Safety Plan (2009) developed by the Caribbean Environmental Health Institute.